Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pertuzumab

- PMLiVE

England’s Cancer Drugs Fund: Naughty or NICE?

The decision to extend the CDF raises questions on the future of cancer drug access on the NHS

- PMLiVE

Levinson resigns from Roche board

Declares conflict of interest due to his position as CEO at Calico

- PMLiVE

Alexion convinces NICE of Soliris’ value

But recommendation of the expensive 'ultra orphan' drug' comes with conditions

- PMLiVE

Major depression in UK cancer patients going untreated

Only 17% of patients reacted to usual NHS therapy according to new research

- PMLiVE

England’s Cancer Drugs Fund receives new funding boost

Gains an extra £160m to pay for drugs not recommended by NICE

- PMLiVE

NICE wants more data on Boehringer’s Jardiance

Pharma company needs to demonstrate cost-effectiveness of its diabetes drug

Biogen Idec building

Final NICE backing for Biogen Idec’s Tecfidera

Oral multiple sclerosis is cleared for NHS use in England

- PMLiVE

Diagnostics are rising up the pharma value chain

Pharma interview: Anssi Pulkkinen from Roche Diagnostics, Finland on the increasing prominence of diagnostics

Roche - Basel

Roche boosts respiratory presence with InterMune purchase

Deal is fourth takeover in three months for Swiss pharma company

- PMLiVE

Easier access to medicines in the UK?

Cutting through the NICE value-based assessment consultation to find out what’s at stake

Easier access to medicines in the UK?

Cutting through the NICE value-based assessment consultation to find out what’s at stake

- PMLiVE

Omega buys pharmacy to understand customers

Will turn Warman-Freed in North London into ‘learning pharmacy’

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links